Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Aquestive Therapeutics ( (AQST) ).
On August 13, 2025, Aquestive Therapeutics announced a $75 million strategic funding agreement with RTW Investments, contingent upon FDA approval of Anaphylm, a sublingual film for treating severe allergic reactions. This financing aims to support the potential commercialization of Anaphylm, strengthening the company’s financial position and offering a novel treatment option for patients. The agreement includes tiered revenue share payments to RTW based on Anaphylm’s net sales in the U.S., with payments ceasing upon reaching specified financial thresholds.
The most recent analyst rating on (AQST) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Aquestive Therapeutics stock, see the AQST Stock Forecast page.
Spark’s Take on AQST Stock
According to Spark, TipRanks’ AI Analyst, AQST is a Neutral.
The overall stock score reflects significant financial difficulties, with declining revenues and high leverage being the most impactful factors. While there is potential for future growth with Anaphylm, current financial instability and negative earnings weigh heavily on the score.
To see Spark’s full report on AQST stock, click here.
More about Aquestive Therapeutics
Aquestive Therapeutics is a pharmaceutical company focused on developing orally administered products to improve patient care through innovative science and delivery technologies. The company has four commercialized products marketed by its licensees globally and is advancing a late-stage proprietary product candidate for severe allergic reactions, including anaphylaxis.
Average Trading Volume: 1,341,074
Technical Sentiment Signal: Strong Buy
Current Market Cap: $377M
See more data about AQST stock on TipRanks’ Stock Analysis page.